Signatures of COVID-19 Severity and Immune Response in the Respiratory Tract Microbiome-Reference-Cited by-同舟云学术

Signatures of COVID-19 Severity and Immune Response in the Respiratory Tract Microbiome

Published:2021-08-31 Issue:4 Volume:12 Page:
ISSN:2150-7511
Container-title:mBio
language:en
Short-container-title:mBio

Author:

Merenstein Carter¹^ORCID,Liang Guanxiang¹,Whiteside Samantha A.²,Cobián-Güemes Ana G.¹,Merlino Madeline S.¹,Taylor Louis J.¹^ORCID,Glascock Abigail¹,Bittinger Kyle³,Tanes Ceylan³,Graham-Wooten Jevon²,Khatib Layla A.²,Fitzgerald Ayannah S.²,Reddy Shantan¹,Baxter Amy E.⁴⁵,Giles Josephine R.⁴⁵,Oldridge Derek A.⁵⁶,Meyer Nuala J.²,Wherry E. John⁴⁵,McGinniss John E.²,Bushman Frederic D.¹^ORCID,Collman Ronald G.²^ORCID

Affiliation:

1. Department of Microbiology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA

2. Pulmonary, Allergy and Critical Care Division, Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA

3. Division of Gastroenterology, Hepatology, and Nutrition, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA

4. Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA

5. Institute for Immunology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA

6. Department of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA

Abstract

COVID-19, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection of the respiratory tract, results in highly variable outcomes ranging from minimal illness to death, but the reasons for this are not well understood. We investigated the respiratory tract bacterial microbiome and small commensal DNA viruses in hospitalized COVID-19 patients and found that each was markedly abnormal compared to that in healthy people and differed from that in critically ill patients without COVID-19.

Funder

HHS | National Institutes of Health

Parker Institute for Cancer Immunotherapy

Allen Institute for Immunology

Mark Foundation for Cancer Research Institute

Publisher

American Society for Microbiology

Subject

Virology,Microbiology

Link

https://journals.asm.org/doi/pdf/10.1128/mBio.01777-21

Reference43 articles.